CellSource , Ltd. EBIT

As of the most recent data (July 2026), 4880.T shows a EBIT of $220M. That compares with $-140M in the prior-year period — up 264.1% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4880.T's EBIT is now $220M (was $-140M) — a 264.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether CellSource , Ltd. is outperforming or lagging.

The Healthcare sector average EBIT is about $110B. CellSource , Ltd. is at $220M, which is lower that average. That is roughly 99.8% below the sector mean. Use the comparison chart on this page to see how 4880.T stacks up against individual peers as well.

Tracking 4880.T's ebit over time shows whether CellSource , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $220M That compares with $-140M in the prior-year period — up 264.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has CellSource , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $220M) with ownership activity and broader fundamentals.